Inceptionr LLC Acquires Shares of 6,999 Nuvalent, Inc. $NUVL

Inceptionr LLC acquired a new stake in shares of Nuvalent, Inc. (NASDAQ:NUVL) during the 1st quarter, HoldingsChannel.com reports. The firm acquired 6,999 shares of the company’s stock, valued at approximately $717,000.

Several other hedge funds have also recently modified their holdings of the stock. GAMMA Investing LLC boosted its position in shares of Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after acquiring an additional 108 shares during the last quarter. NBC Securities Inc. bought a new stake in Nuvalent in the 4th quarter valued at $125,000. KBC Group NV increased its holdings in Nuvalent by 24.1% in the 4th quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after acquiring an additional 297 shares during the last quarter. Portland Investment Counsel Inc. purchased a new stake in Nuvalent in the 4th quarter worth $201,000. Finally, Swiss Life Asset Management Ltd purchased a new stake in Nuvalent in the 4th quarter worth $202,000. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on NUVL shares. Wedbush downgraded shares of Nuvalent from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $125.00 to $124.00 in a report on Tuesday, June 9th. Lifesci Capital cut Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 target price on the stock. in a report on Tuesday, June 9th. UBS Group downgraded Nuvalent from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $138.00 to $124.00 in a research report on Wednesday, June 10th. Piper Sandler lowered Nuvalent from an “overweight” rating to a “neutral” rating and set a $124.00 price target for the company. in a research note on Tuesday, June 9th. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $124.00 price target (up from $116.00) on shares of Nuvalent in a report on Tuesday, June 9th. Four investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $127.73.

Nuvalent Price Performance

Shares of NASDAQ:NUVL opened at $123.96 on Friday. Nuvalent, Inc. has a 52 week low of $71.13 and a 52 week high of $123.99. The stock has a market capitalization of $9.79 billion, a P/E ratio of -20.46 and a beta of 1.14. The firm has a fifty day simple moving average of $115.86 and a two-hundred day simple moving average of $107.33.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period in the previous year, the company posted ($1.18) EPS. On average, analysts expect that Nuvalent, Inc. will post -5.74 earnings per share for the current year.

Insider Buying and Selling at Nuvalent

In other Nuvalent news, CEO James Richard Porter sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $101.69, for a total transaction of $3,050,700.00. Following the sale, the chief executive officer directly owned 324,879 shares of the company’s stock, valued at $33,036,945.51. The trade was a 8.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Alexandra Balcom sold 11,430 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $123.58, for a total value of $1,412,519.40. Following the sale, the chief financial officer owned 85,533 shares in the company, valued at approximately $10,570,168.14. This trade represents a 11.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 125,971 shares of company stock worth $13,358,939 in the last 90 days. 5.02% of the stock is currently owned by insiders.

Nuvalent Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.